A Phase IB/II Study of SNS-062 in Patients with Persistent or Recurrent B-Cell Cancers


Full Title

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton’s Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies


The purpose of this study is to find the highest dose of the investigational drug SNS-062 that can be given safely in patients with B-cell cancers that have continued to grow or came back after prior treatment and to observe how effective it is. SNS-062 works by blocking a protein inside cancer cells called Bruton’s tyrosine kinase (BTK), which helps cancer cells to live, grow, and spread.

Laboratory studies suggest that SNS-062 may be active against cancers that have developed resistance to another BTK inhibitor called ibrutinib. SNS-062 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a B-cell cancer that has continued to grow or came back despite at least two regimens of prior treatment. Examples include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytoid lymphoma/Waldenstrom’s macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma of the activated B-cell subtype (DLBCL-ABC), and follicular lymphoma (FL).
  • Patients with CLL, LPL/WM, and MCL must have previously received a BTK inhibitor.
  • Patients should recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anthony Mato at 212-639-8596.





Disease Status

Newly Diagnosed & Relapsed/Refractory